Dimopoulos M, Tedeschi A, Trotman J, et al. Multinational, randomized phase 3 trial of ibrutinib-rituximab vs placebo-rituximab with Waldenström’s macroglobulinemia. EHA 2018, abstract S852.
Fysieke inactiviteit de grootste modificeerbare risicofactor in de geneeskunde
jan 2024 | Leukemie, Lymfoom, MDS, MM, MPN